TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02630147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vanilla scent
Description: A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vanilla scent
Description: A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
Study: NCT05088733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng Jie Du therapy
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine medical care
Description: Routine medical care
Study: NCT03602547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus JS001
Description: CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study: NCT04394078

Intervention type: OTHER
Intervention: Online survey
Description: Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
Study: NCT04034056

Intervention type: DRUG
Intervention: Obinutuzumab
Description: Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
Study: NCT01263223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT03234049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
Study: NCT01636258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: Every other week
Study: NCT04278833

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone or Betamethasone
Description: Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
Study: NCT02530320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
Study: NCT03506646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be given a gelatin tablet to serve as the control condition. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet root juice
Description: Beet root juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
Study: NCT05043324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCov-220 (1)
Description: The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCov-220 (2)
Description: The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
Study: NCT05165277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Study: NCT02118896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506E
Description: oral
Study: NCT05179434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde renal graft reperfusion
Description: Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antegrade renal graft reperfusion (without retrograde reperfusion)
Description: Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
Study: NCT03310606

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of serum and peritoneal of the B lactam used for antibiotic treatment
Description: Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
Study: NCT00244881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04484987

Intervention type: OTHER
Group type: OTHER
Intervention: 9 hours daily eating window
Description: Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: 15 hours daily eating window
Description: Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
Study: NCT02572271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rubins Mastopexy
Description: The surgical technique described by Rubin is performed. No other intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOPOSAM
Description: The surgical technique LOPOSAM is performed. No other intervention.
Study: NCT02841137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: comparison of different dosages of drug towards the active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: comparison of different dosages of drug towards the active comparator
Study: NCT03126682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin SR 300Mg Extended-Release Tablet
Description: Wellbutrin SR 300Mg Extended-Release Tablet
Study: NCT04851977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Vaccine
Description: BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo \[saline/mannitol\] by IM injection to the deltoid region of the other arm, given sequentially).
Study: NCT01048138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden Lactate
Description: 5mg IV(in the vein)every 6 hours for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg IV(in the vein)every 6 hours for 10 days
Study: NCT02681926

Intervention type: PROCEDURE
Intervention: VISITAG
Description: Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology

Intervention type: PROCEDURE
Intervention: VISITAG
Description: Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
Study: NCT01607034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 150 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 150 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 150 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 150 mg single dose
Study: NCT01736852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRB
Description: Labor induction using the CRB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitocin
Description: Labor induction using Pitocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitocin
Description: Labor induction using Pitocin
Study: NCT00870311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
Study: NCT02397083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System
Description: Placed in the uterus
Study: NCT04851977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Vaccine
Description: BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm \[one injection of 10 μg rRSV-G protein/10 μg CsA per arm\], given sequentially). The high dose is twice the strength of the low dose.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially).
Study: NCT04480164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NDMC
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
Study: NCT01732835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAART 300 Annuloplasty Device
Description: Implantation of HAART 300 Annuloplasty Device for aortic valve repair
Study: NCT04136106

Intervention type: DRUG
Intervention: IL-2
Description: IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
Study: NCT01369628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: 1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks
Study: NCT00583492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP
Description: Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
Study: NCT00380640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: This group will receive the active intervention (trimethoprim) first, followed by the placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: This group will start the study with placebo, followed by the active intervention (trimethoprim).
Study: NCT01070810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W
Description: Dextrose 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine 200mg in 50ml D5W
Study: NCT02533882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement to Music

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Yoga
Study: NCT00187798

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin HCl
Description: Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
Study: NCT02323724

Intervention type: GENETIC
Intervention: BRAF V600E mutation by pyrosequencing technique
Study: NCT04329962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Powder Food Product
Description: Consume blueberry powder confection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Powder Food Product
Description: Consume blueberry powder confection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume blueberry extract confection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume blueberry extract confection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03880578

Intervention type: DRUG
Intervention: Levothyroxine Sodium
Description: thyroid hormone replacement

Intervention type: DRUG
Intervention: Levothyroxine Sodium
Description: thyroid hormone replacement

Intervention type: DRUG
Intervention: Levothyroxine Sodium
Description: thyroid hormone replacement
Study: NCT01544712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression with autologous bone marrow implantation
Description: core biopsy with injection of 40 ml concentrated autologous bone marrow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression of the femoral head
Description: core biopsy with injection of 40 ml saline solution in place of bone marrow.
Study: NCT04212507

Intervention type: DIAGNOSTIC_TEST
Intervention: The serum level of Claudin-3 and intestinal Fatty acid binding protein
Description: The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: The serum level of Claudin-3 and intestinal Fatty acid binding protein
Description: The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
Study: NCT03569956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 556 Razor
Description: In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 556 Razor
Description: In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
Study: NCT03083288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Description: \[18F\]FluorThanatrace is a radiotracer for PET/CT
Study: NCT00890461

Intervention type: RADIATION
Intervention: CT scan of the chest without contrast
Description: Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
Study: NCT05116735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic partial cystectomy with omentoplasty
Description: laparoscopic partial cystectomy with omentoplasty
Study: NCT01075659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
Study: NCT04177108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atezolizumab
Description: Placebo was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atezolizumab
Description: Placebo was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ipatasertib
Description: Placebo was administered as per the dosage regimen mentioned in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ipatasertib
Description: Placebo was administered as per the dosage regimen mentioned in arm descriptions.
Study: NCT02785367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood samples
Description: After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth.
Study: NCT00945516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bona stent® (Flared end FCSEMS)
Description: Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hanarostent® (Anchoring FCSEMS)
Description: Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.